Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
Closed Posted
- Opportunity number
- RFA-CA-25-003
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Up to $150,000
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Categories
-
- Education
- Health
- Eligible applicants
-
- City/Township Governments
- Tribal Governments (Federally Recognized)
- 501(c)(3) Nonprofits
- Other
- Small Businesses
- County Governments
- Special District Governments
- Higher Education Inst. (Public)
- State Governments
- Independent School Districts
- Non-501(c)(3) Nonprofits
- Higher Education Inst. (Private)
- Public or Indian Housing Auth.
- Tribal Organizations (Not Federally Recognized)
- For Profit Organizations
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Cancer Institute (NCI) is soliciting grant applications for innovative biospecimen science technologies aimed at improving the quality and handling of cancer research samples. This funding opportunity seeks tools, devices, instrumentation, and methods that can address pre-analytical degradation of targeted analytes during collection, processing, handling, and storage of cancer-relevant biospecimens. Eligible applicants include city/township governments, tribal organizations, nonprofits, small businesses, higher education institutions, and state governments. The primary objective is to develop technologies that can preserve sample integrity, establish quality assessment criteria, and enhance research capabilities in cancer biology, early detection, screening, clinical diagnosis, treatment, and epidemiology. Applications will be evaluated based on the innovative nature of the proposed technologies, their potential to advance cancer research, and their ability to address health disparities.
The grant opportunity is part of the NCI's Innovative Molecular Analysis Technologies (IMAT) Program and falls under the Cancer Detection and Diagnosis Research program (CFDA 93.394). While specific award amounts are not detailed, the funding is designed to support early-stage research and technology development. The posted date is December 16, 2024, with a proposal due date of December 9, 2025. Research will be conducted at the recipient's facilities across the United States, with a focus on developing cutting-edge tools that can potentially improve cancer research and diagnostic methodologies.
Synopsis
2 versions
Update #2 · Latest ·
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies to improve the quality and handling of samples used for cancer research or clinical care. This includes tools with new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This NOFO will support the development of tools, devices, instrumentation, and associated methods for the collection, handling, processing, preservation, or storage of cancer-relevant biospecimens and their derivatives. This includes tools with new capabilities to preserve or protect sample integrity, establish verification criteria for quality assessment/quality control, and address issues related to pre-analytical degradation of target analytes. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, and/or address issues associated with cancer health disparities.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Update #1 ·
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies to improve the quality and handling of samples used for cancer research or clinical care. This includes tools with new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This NOFO will support the development of tools, devices, instrumentation, and associated methods for the collection, handling, processing, preservation, or storage of cancer-relevant biospecimens and their derivatives. This includes tools with new capabilities to preserve or protect sample integrity, establish verification criteria for quality assessment/quality control, and address issues related to pre-analytical degradation of target analytes. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, and/or address issues associated with cancer health disparities. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Files
| File | Type | Posted |
|---|---|---|
| RFA-CA-25-003-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity